XenoSTART Taps New President to Scale Advanced Cancer Research Platform

SAN ANTONIO, TX – February 24, 2026 – The START Center for Cancer Research today announced a key leadership appointment, naming Frank Smith, PhD, MBA, as President of its preclinical business unit, XenoSTART. The move signals a strategic push to scale the company's influential patient-derived xenograft (PDX) platform and solidify its position as a critical partner for global oncology drug developers.

Dr. Smith will take the helm of XenoSTART's operations, tasked with enhancing its project delivery, reinforcing quality systems, and providing the R&D leadership necessary to expand the business. The appointment is seen as a deliberate effort to harness XenoSTART’s unique assets to accelerate the journey of new cancer therapies from the laboratory to the clinic.

"We are thrilled to welcome Frank as President of XenoSTART," said Nick Slack, MBE, Chairman and CEO of START. "XenoSTART is a critical link between drug discovery and the clinic. Frank brings the operational discipline to scale our patient-derived xenograft (PDX) platform, a strong commitment to quality, and the leadership skills to inspire excellence from our XenoSTART team. I'm confident he will further position XenoSTART as the leading provider of patient-derived translational research in oncology."

A Strategic Move in a Competitive Landscape

Dr. Smith’s appointment comes as the preclinical oncology Contract Research Organization (CRO) market experiences robust growth and fierce competition. The global market for oncology-based preclinical CROs was valued at over $3 billion in 2023 and is projected to more than double to $6.5 billion by 2032. A significant driver of this growth is the increasing reliance on advanced, clinically relevant models like the PDX systems that XenoSTART specializes in.

In this crowded field, which includes major players like Crown Bioscience and Charles River Laboratories, XenoSTART has carved out a distinct niche. Its primary advantage lies in its vast and meticulously curated library of over 2,800 PDX models. Crucially, these are not generic models; each is sourced directly from patients enrolled in clinical trials across START's global network of community oncology centers. This provides an unparalleled level of clinical annotation, including patient histories, molecular profiles, and in vivo drug response data, making the models a powerful tool for predicting how a new drug might behave in a real-world patient population.

Bringing in an executive with Dr. Smith's operational acumen is a clear strategy to capitalize on this unique asset. By optimizing internal processes and scaling the platform's capacity, XenoSTART aims to more effectively serve its biopharma partners and solidify its leadership in a market that increasingly values data fidelity and clinical relevance.

The Power of Patient-Derived Models

At the heart of XenoSTART's value proposition is the scientific superiority of PDX models over traditional preclinical tools. For decades, researchers relied on cancer cell lines grown in labs for generations, which often lost the complex characteristics of the original tumor. PDX models, by contrast, involve implanting a patient's tumor tissue directly into an immune-compromised mouse. This method preserves the tumor's original architecture, genetic heterogeneity, and molecular signatures with remarkable fidelity.

This high-fidelity replication has profound implications for drug development. Studies have shown a strong correlation between how a drug performs in a PDX model and the clinical outcome in the corresponding patient, with some research indicating concordance rates as high as 88%. This predictive power allows drug developers to "fail faster and cheaper," identifying unpromising candidates early and focusing resources on those with the highest probability of success. Furthermore, these models are invaluable for studying the mechanisms of drug resistance and testing novel combination therapies that mirror complex clinical scenarios.

While the technology is not without its challenges—including high costs, lengthy development times, and the need for immune-compromised hosts that limit immunotherapy research—its impact is undeniable. The industry is actively working on next-generation solutions, such as humanized models with reconstituted immune systems, to overcome these limitations. For now, the existing PDX platforms represent the gold standard for translational oncology research.

An Operational Expert for a Scientific Engine

To steer this sophisticated scientific engine, START has chosen a leader with a diverse and highly relevant background. Dr. Smith holds a PhD in Biochemistry, Biophysics and Molecular Biology from Temple University and an MBA from Villanova University, giving him a rare fluency in both the scientific and business languages of the biopharmaceutical industry. His previous leadership roles at major industry players—including the global CRO Charles River, the pharmaceutical giant GSK, and the specialized PDX provider Champions Oncology—have prepared him for the unique challenges of scaling a complex preclinical organization.

His mandate at XenoSTART is multifaceted: build and develop a best-in-class team, streamline laboratory operations and logistics, and deploy technology to enhance efficiency. This focus on operational excellence is critical for a business that must deliver precise, reliable, and timely data to partners who are making multi-million dollar decisions based on the results.

Dr. Smith articulated a vision that directly aligns with START's patient-centric mission. "XenoSTART sits at the forefront of oncology drug development," he stated. "My focus will be on scaling that platform by advancing our operations, investing in our people, and partnering even more closely with sponsors to help them answer the most important questions sooner. Ultimately, every operational improvement we make is about one thing: getting new therapies to patients faster."

Bridging the Gap from Lab to Clinic

The appointment of Dr. Smith is not just about optimizing a single business unit; it's about strengthening a vital link in the entire cancer drug development ecosystem that The START Center for Cancer Research has built. START's foundation is its global network of 15 clinical trial sites, which have conducted over 1,000 early-phase trials and contributed to the approval of 50 new cancer therapies by the FDA or EMA.

This clinical powerhouse directly feeds and informs the preclinical work at XenoSTART. When a new PDX model is created from a patient in a START trial, it enters the XenoSTART library with a rich backstory that is invaluable for future research. This seamless integration of clinical and preclinical operations allows the organization to create a virtuous cycle of discovery, where insights from the clinic improve the models in the lab, and data from the lab helps design smarter, more effective trials for patients.

By leveraging these advanced models, drug developers can de-risk their programs, identify biomarkers for patient stratification, and design more efficient clinical studies. This integrated approach can dramatically shorten the notoriously long and expensive timeline of oncology drug development. By providing more predictive data earlier in the process, XenoSTART enables its partners to make more confident decisions, accelerating the passage of the most promising new anti-cancer agents from trials to treatments and delivering on the organization's ultimate promise of hope for patients around the world.